Athebio

Athebio is a privately held biotech company founded in 2019, leveraging its Athebody® DARPin platform to empower drug developers with a versatile, 'plug & play' scaffold for creating superior targeted therapeutics. The company's mission is to explore and unleash the therapeutic potential of repeat proteins, offering partners a technology characterized by high specificity, solubility, stability, and ease of manufacturing. Athebio's business model is centered on strategic partnerships and technology transfer, as evidenced by its collaboration with POINT Biopharma to develop targeted radioligands.

The Athebody® platform is a proprietary technology based on Designed Ankyrin Repeat Proteins (DARPins), a small, stable, and modular protein scaffold used to create highly specific binders for targeted biotherapeutics across multiple modalities.

Athebio's main competitor in the DARPin space is Molecular Partners AG. It also competes with companies using alternative scaffolds like Affibodies, Adnectins, and nanobodies. Differentiation is based on its efficient discovery engine, partnership-focused 'plug & play' model, and application in emerging areas like targeted radiotherapy.